Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Assets Average (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Assets Average for 6 consecutive years, with $645.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 28.32% to $645.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $645.7 million, a 28.32% decrease, with the full-year FY2025 number at $746.3 million, down 12.98% from a year prior.
  • Assets Average was $645.7 million for Q4 2025 at Relay Therapeutics, down from $699.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.1 billion in Q4 2022 to a low of $645.7 million in Q4 2025.
  • A 5-year average of $867.4 million and a median of $847.0 million in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: soared 48.49% in 2022, then decreased 28.32% in 2025.
  • Relay Therapeutics' Assets Average stood at $840.0 million in 2021, then soared by 35.02% to $1.1 billion in 2022, then decreased by 22.81% to $875.5 million in 2023, then increased by 2.88% to $900.7 million in 2024, then fell by 28.32% to $645.7 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Assets Average are $645.7 million (Q4 2025), $699.4 million (Q3 2025), and $764.1 million (Q2 2025).